Founded in 2009 by pioneers in biopharmaceuticals, Renova Therapeutics is working to create a portfolio of definitive one-time gene therapy treatments as well as peptide infusion therapies to restore health to people suffering from cardiovascular and metabolic diseases. The first indications the company is pursuing are gene therapies for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. Along with single-dose gene therapies, Renova Therapeutics is also developing a peptide infusion treatment for the periods in which CHF patients are hospitalized for Acute Decompensated Heart Failure.
Our investigational gene therapies are based on carefully validated and proprietary research into disease mechanisms and the founders’ nearly 50 combined years of work in the gene therapy field. This experience forms the basis of the company’s efforts to generate an entirely original platform of therapeutics and delivery systems that may provide durable, life-long treatments for chronic diseases.
We believe that by making once-for-life gene therapies widely accessible, we can help renew millions of lives and positively impact rising health care costs.
- Our mission: Creating transformational gene therapies and peptide infusions that treat the most prevalent diseases to restore health and renew life
- Our vision: A future in which we are able to permanently treat chronic diseases with gene and peptide therapies